title: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.
abstract: BACKGROUND
  The efficacy of infliximab in ulcerative colitis (UC) and indeterminate colitis has been poorly assessed and preliminary results are conflicting.
  
  
  METHODS
  The records of 30 patients treated with infliximab for ulcerative colitis (n=19) or indeterminate colitis (n=11) were reviewed. Infliximab was given because of steroid resistance (n=18), dependence (n=5) or intolerance (n=7); five patients had failed on cyclosporin; 19 patients had a severe flare-up.
  
  
  RESULTS
  Median duration of follow-up was 10 months. In 28 patients with active disease, the response rate was 75% at day 7, with 43% having a complete remission, and 50% at month 1, with 32% having a complete remission. Among the 22 responders, the probability of relapse was 73% at month 6. The probability of complete remission without steroids, taking into account the re-treatment for relapse (n=11), was 57% (95% confidence interval (CI): 45% to 69%) at month 6. The probability of colectomy was 33% (95% CI: 23% to 43%) at month 12. In indeterminate colitis, response rate was only 50% at day 7 and 30% at month 1. Concomitant use of antimetabolite agents was associated with better results.
  
  
  CONCLUSIONS
  Infliximab was able to induce a rapid response in some patients with UC or indeterminate colitis refractory to conventional treatment. Long-term results were less favourable, with frequent relapses, and about one-third of the patients required a colectomy.
authors.affiliation: Department of Gastroenterology, Hôpital Saint-Louis, Paris, France. jean-marc.gornet@sls.ap-hop-paris.fr
authors.forename: J-M
authors.initials: JM
authors.lastname: Gornet
authors.forename: S
authors.initials: S
authors.lastname: Couve
authors.forename: Z
authors.initials: Z
authors.lastname: Hassani
authors.forename: J-C
authors.initials: JC
authors.lastname: Delchier
authors.forename: P
authors.initials: P
authors.lastname: Marteau
authors.forename: J
authors.initials: J
authors.lastname: Cosnes
authors.forename: Y
authors.initials: Y
authors.lastname: Bouhnik
authors.forename: J-L
authors.initials: JL
authors.lastname: Dupas
authors.forename: R
authors.initials: R
authors.lastname: Modigliani
authors.forename: F
authors.initials: F
authors.lastname: Taillard
authors.forename: M
authors.initials: M
authors.lastname: Lemann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002908:Chronic Disease; D015331:Cohort Studies; D003082:Colectomy; D003092:Colitis / Q000188:drug therapy*; D003093:Colitis, Ulcerative / Q000188:drug therapy; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab